{"entity": "researcher", "timestamp": "2026-09-28T23:50:49.802Z", "family": "Chiorazzi", "given": "N", "initials": "N", "orcid": "0000-0003-1023-6650", "affiliations": ["Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/758e96d46b454103bb8fe98a811c0ba0.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/758e96d46b454103bb8fe98a811c0ba0"}}, "publications": [{"entity": "publication", "iuid": "1b9f19391dd341659f4ad9469d9b0f4a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/1b9f19391dd341659f4ad9469d9b0f4a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/1b9f19391dd341659f4ad9469d9b0f4a"}}, "title": "EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.", "authors": [{"family": "Young", "given": "E", "initials": "E"}, {"family": "Noerenberg", "given": "D", "initials": "D"}, {"family": "Mansouri", "given": "L", "initials": "L"}, {"family": "Ljungstr\u00f6m", "given": "V", "initials": "V"}, {"family": "Frick", "given": "M", "initials": "M"}, {"family": "Sutton", "given": "L-A", "initials": "LA"}, {"family": "Blakemore", "given": "S J", "initials": "SJ"}, {"family": "Galan-Sousa", "given": "J", "initials": "J"}, {"family": "Plevova", "given": "K", "initials": "K"}, {"family": "Baliakas", "given": "P", "initials": "P"}, {"family": "Rossi", "given": "D", "initials": "D"}, {"family": "Clifford", "given": "R", "initials": "R"}, {"family": "Roos-Weil", "given": "D", "initials": "D"}, {"family": "Navrkalova", "given": "V", "initials": "V"}, {"family": "D\u00f6rken", "given": "B", "initials": "B"}, {"family": "Schmitt", "given": "C A", "initials": "CA"}, {"family": "Smedby", "given": "K E", "initials": "KE"}, {"family": "Juliusson", "given": "G", "initials": "G"}, {"family": "Giacopelli", "given": "B", "initials": "B"}, {"family": "Blachly", "given": "J S", "initials": "JS"}, {"family": "Belessi", "given": "C", "initials": "C"}, {"family": "Panagiotidis", "given": "P", "initials": "P"}, {"family": "Chiorazzi", "given": "N", "initials": "N", "orcid": "0000-0003-1023-6650", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/758e96d46b454103bb8fe98a811c0ba0.json"}}, {"family": "Davi", "given": "F", "initials": "F"}, {"family": "Langerak", "given": "A W", "initials": "AW"}, {"family": "Oscier", "given": "D", "initials": "D"}, {"family": "Schuh", "given": "A", "initials": "A"}, {"family": "Gaidano", "given": "G", "initials": "G"}, {"family": "Ghia", "given": "P", "initials": "P", "orcid": "0000-0003-3750-7342", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/475d35f1a3c446819b2f24be819c2dee.json"}}, {"family": "Xu", "given": "W", "initials": "W"}, {"family": "Fan", "given": "L", "initials": "L"}, {"family": "Bernard", "given": "O A", "initials": "OA"}, {"family": "Nguyen-Khac", "given": "F", "initials": "F"}, {"family": "Rassenti", "given": "L", "initials": "L"}, {"family": "Li", "given": "J", "initials": "J"}, {"family": "Kipps", "given": "T J", "initials": "TJ"}, {"family": "Stamatopoulos", "given": "K", "initials": "K"}, {"family": "Pospisilova", "given": "S", "initials": "S"}, {"family": "Zenz", "given": "T", "initials": "T"}, {"family": "Oakes", "given": "C C", "initials": "CC"}, {"family": "Strefford", "given": "J C", "initials": "JC"}, {"family": "Rosenquist", "given": "R", "initials": "R"}, {"family": "Damm", "given": "F", "initials": "F"}], "type": "journal article", "published": "2017-07-00", "journal": {"title": "Leukemia", "issn": "1476-5551", "volume": "31", "issue": "7", "pages": "1547-1554", "issn-l": "0887-6924"}, "abstract": "Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hotspot region including a screening (n=1283) and two validation cohorts (UK CLL4 trial patients, n=366; CLL Research Consortium (CRC) patients, n=490). Targeted deep-sequencing of 27 known/postulated CLL driver genes was also performed in 38 EGR2-mutated patients to assess concurrent mutations. EGR2 mutations were detected in 91/2403 (3.8%) investigated cases, and associated with younger age at diagnosis, advanced clinical stage, high CD38 expression and unmutated IGHV genes. EGR2-mutated patients frequently carried ATM lesions (42%), TP53 aberrations (18%) and NOTCH1/FBXW7 mutations (16%). EGR2 mutations independently predicted shorter time-to-first-treatment (TTFT) and overall survival (OS) in the screening cohort; they were confirmed associated with reduced TTFT and OS in the CRC cohort and independently predicted short OS from randomization in the UK CLL4 cohort. A particularly dismal outcome was observed among EGR2-mutated patients who also carried TP53 aberrations. In summary, EGR2 mutations were independently associated with an unfavorable prognosis, comparable to CLL patients carrying TP53 aberrations, suggesting that EGR2-mutated patients represent a new patient subgroup with very poor outcome.", "doi": "10.1038/leu.2016.359", "pmid": "27890934", "labels": [], "xrefs": [{"db": "mid", "key": "NIHMS1068606"}, {"db": "pmc", "key": "PMC7001738"}, {"db": "pii", "key": "leu2016359"}], "notes": [], "created": "2018-12-05T12:11:01.231Z", "modified": "2026-09-23T09:22:45.774Z"}]}